Quick Read <\/p>\n
NVIDIA and Eli Lilly’s $1 billion AI drug discovery partnership makes both stocks the primary public vehicles for programmable biology exposure.<\/p>\n
Jeff Bezos reportedly committed $3 billion to longevity startup Altos Labs, while Brian Armstrong’s NewLimit tripled in value to $3 billion.<\/p>\n
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and Eli Lilly didn’t make the cut. Grab the names FREE today<\/a>.<\/p>\n Over recent months, a striking pattern has emerged: major capital allocators are positioning around AI-driven biology and longevity. According to a Polymarket post on X, Coinbase (NASDAQ:COIN<\/a>) founder Brian Armstrong’s longevity startup NewLimit has tripled in value to $3.1 billion. That post sparked a viral reply thread from podcast host Mgoes (@m_goes_distance), cataloging billionaire and corporate bets on programmable biology.<\/p>\n For enterprising investors, the hook is simple. When visionary billionaires and blue-chip operators converge on the same theme, it’s worth understanding what they see. Most named startups are privately held, leaving NVIDIA (NASDAQ:NVDA<\/a>) and Eli Lilly (NYSE:LLY<\/a>) as the two realistic public-market entry points.<\/p>\n The Verified Anchor: NVIDIA’s $1 Billion Bet With Eli Lilly <\/p>\n In January, NVIDIA and Eli Lilly announced a first-of-its-kind AI co-innovation lab, committing up to $1 billion over five years to industrialize drug discovery, with the lab based in the San Francisco Bay Area and running on NVIDIA’s BioNeMo platform and Vera Rubin architecture. Eli Lilly also built the “LillyPod” supercomputer with NVIDIA GPUs to accelerate drug discovery.<\/p>\n The buildout is structural. NVIDIA CEO Jensen Huang has called the broader AI buildout “the largest infrastructure expansion in human history,” and pharma is increasingly part of that buildout.<\/p>\n The Mgoes Thread: Big Claims, Unverified <\/p>\n The viral X reply by Mgoes goes further. According to the Mgoes post, Amazon (NASDAQ:AMZN<\/a>) founder Jeff Bezos put $3 billion behind Altos Labs, DeepMind Technologies CEO Demis Hassabis raised $2.1 billion for Isomorphic Labs, and Anthropic acquired Coefficient Bio for $400 million (I have not independently verified those figures).<\/p>\n Mgoes also asserts that longevity biotech raised $3.74 billion in Q1 2026, which the post claims is 56% ahead of Q1 2025 (again, I haven’t verified these figures), framing the thesis as “biotech is starting to move like AI did 3 years ago” with the smart money positioning rather than speculating. Even if the specific dollar figures are debatable, the corporate footprint around NVIDIA’s BioNeMo ecosystem is certainly notable.<\/p>\n